Organovo Holdings logo
Organovo Holdings ONVO
report update icon

Annual report 2026
added 07-14-2026

Organovo Holdings Financial Ratios 2026-2008 | ONVO

Brief overview of Organovo Holdings's valuation and returns

This overview follows the five latest available observations from 2019 through 2025.

The valuation comparison uses P/S 21.55x (median 23.08x), P/B 0.3x (median 0.52x). Multiples are on average 24.8% below their own medians. Shares look cheaper than their recent historical valuation.

Current measures of operating quality are ROE -23.7%, ROA -17%, ROCE -120.2%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.

Valuation takeaway

Organovo Holdings's restrained price comes with modest current quality. Better efficiency is needed for revaluation.

Annual Financial Ratios Organovo Holdings

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

P/E

- -1.2 -0.1 -0.5 - -1.2 -2.9 -4.3 -3.8 -7.4 -6.5 -12.0 -16.5 -337.1 -4.2 - - - -

P/S

- 21.5 6.9 23.1 - - 24.8 37.3 28.9 67.0 169.5 633.3 1127.0 24700.0 153.9 - - - -

EPS

-5.3 -1.7 -19.2 -2.0 -1.3 -2.4 -2.8 -0.2 -0.3 -0.4 -0.4 -0.4 -0.3 - -1.0 -0.2 -0.1 - -

EV (Enterprise Value)

3.46 M -4.05 M 594 K -1.78 M -25.6 M -16.7 M 28.9 M 83.2 M 94.5 M 228 M 195 M 316 M 381 M 5.43 B 191 M -329 K -285 K -141 K -

EBITDA per Share

-4.35 -8.44 -19.4 -2 -1.3 -2.43 -3.17 -4.56 -6.34 -7.66 -8.19 -7.49 -5.54 -0.064 -4.23 - -0.08 - -

EV/EBITDA

-0.3 0.3 -0.0 0.1 2.3 1.0 -1.3 -3.0 -2.6 -5.9 -5.0 -10.4 -18.7 -1371.7 -18.6 - 0.3 - -

PEG

- -0.01 -0.0 0.03 - 0.06 -0.07 -0.15 -0.21 -1.12 0.66 1.4 0.01 -3.42 0.0 - - - -

P/B

- 0.3 0.2 0.6 - 0.5 2.0 3.2 3.0 4.5 4.0 7.4 8.8 605.8 -34.7 - - - -

P/CF

- -0.3 -0.1 -0.7 - -1.6 -3.7 -5.6 -4.6 -9.3 -8.0 -17.1 -27.0 -1861.0 -18.3 - - - -

ROE %

1259.60 -23.71 -4030.49 -112.59 -37.90 -42.93 -70.26 -73.38 -78.06 -61.65 -62.04 -61.78 -53.53 -179.71 821.29 - 58.19 90.27 102.08

ROA %

-187.42 -16.98 -231.08 -84.97 -34.38 -42.15 -65.79 -65.57 -69.85 -55.58 -57.08 -56.24 -51.50 -92.75 -260.03 - - - -

ROCE %

1045.22 -120.24 -4144.51 -115.67 -38.00 -42.93 -80.64 -73.94 -78.09 -61.07 -61.25 -62.18 -42.76 -44.78 176.30 - 51.20 - -

Current Ratio

0.9 3.5 2.3 4.1 10.8 - 15.6 10.3 10.0 10.8 14.2 10.8 26.0 1.9 0.7 - - - -

DSO

86.4 79.8 309.7 75.0 - - 18.4 65.9 81.5 55.8 63.7 - - 165.9 49.4 - - - -

DIO

- 10840.5 - - - - - 371.1 298.4 210.0 - - - - - - - - -

DPO

- 82891.5 - - - - 801.2 475.6 164.4 447.1 - - - - - - - - -

Operating Cycle

86.4 10920.3 309.8 75.0 - - 18.4 436.9 379.9 265.8 - - - - - - - - -

Cash Conversion Cycle

86.4 -71971.2 309.8 75.0 - - -782.8 -38.6 215.5 -181.3 - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Organovo Holdings

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-1.03 -0.98 -1.14 - -2.28 -1.68 -2.74 - -0.4 -0.46 -0.46 - -0.37 -0.38 -0.37 - -0.4 -1.1 -0.69 - -0.37 -0.37 -1.36 -0.02 -0.6 -0.03 -0.05 -0.05 -0.06 -0.06 -0.05 -0.07 -0.07 -0.09 -0.1 -0.1 -0.09 -0.09 -0.1 -0.09 -0.11 -0.11 -0.12 -0.1 -0.09 -0.09 -0.11 -0.08 -0.07 -0.14 -0.21 -0.26 -0.2 0.87 0.07 -1.17 -0.01 -0.07 -0.01 -0.04

EBITDA per Share

- - -1.14 - - - -2.71 - - - -0.47 - -0.39 -0.36 -0.37 - -0.4 -1.09 -0.69 - -0.36 -0.36 -1.36 -0.02 -0.8 -0.03 -0.05 -0.05 -0.06 -0.05 -0.05 - -0.07 -0.09 -0.09 - -0.1 -0.27 -0.19 - -0.11 -0.32 -0.21 - -0.09 -0.27 -0.19 - -0.06 -0.19 -0.13 -0.06 -0.06 -0.18 -0.11 -0.04 - -0.05 -0.04 -0.02

ROE %

-1073.40 -1959.79 -1993.03 -1066.44 -1124.74 -236.06 -214.02 -139.74 -154.38 -110.73 -76.77 -39.55 -50.74 -47.28 -61.88 -45.85 -52.31 -53.22 -37.91 -67.23 -71.17 -70.71 -68.99 -50.30 -57.32 -63.62 -69.24 -65.93 -65.22 -63.31 -65.03 -68.55 -68.93 -66.42 -66.50 -66.07 -63.08 -64.71 -60.19 -56.17 -59.50 -58.84 -58.19 -65.22 -61.10 -57.32 -81.52 -266.24 -432.64 -241.60 -82.27 943.95 1822.93 1644.95 1761.93 944.30 484.08 239.03 3.65 239.03

ROA %

-178.35 -229.35 -240.82 -162.72 -203.31 -154.21 -152.26 -103.66 -116.68 -89.11 -65.23 -35.44 -45.41 -42.37 -57.05 -43.16 -49.51 -51.17 -36.75 -65.07 -68.47 -67.59 -64.35 -43.91 -49.74 -55.10 -61.19 -59.65 -59.03 -57.45 -59.07 -62.49 -62.95 -60.98 -61.01 -60.69 -58.26 -59.70 -55.85 -52.23 -55.13 -54.53 -54.10 -60.56 -57.50 -54.16 -77.07 -155.77 -235.72 -282.74 -319.03 -670.01 -907.12 -853.11 -1092.67 -648.85 -630.09 -311.13 -4.75 -311.13

ROCE %

-1082.53 -1973.35 -2006.93 -1074.44 -1133.97 -240.75 -218.54 -143.81 -158.88 -114.43 -79.18 -40.20 -51.38 -47.49 -62.05 -55.40 -67.41 -68.23 -52.74 -60.59 -71.05 -77.12 -81.49 -64.27 -71.78 -71.99 -71.94 -67.58 -65.89 -63.87 -65.48 -52.48 -66.07 -63.38 -98.11 -100.00 -115.17 -116.75 -103.29 -77.98 -92.39 -91.63 -93.75 -91.27 -100.76 -95.85 -80.95 -171.53 -216.41 -151.81 25.75 256.46 326.40 305.24 188.51 118.77 86.60 33.94 25.83 26.83

Current Ratio

2.8 3.7 4.9 3.5 1.1 2.2 3.4 2.3 3.3 4.1 5.0 4.1 9.0 9.6 10.6 10.8 9.2 49.8 - 55.4 - - - 15.7 13.3 5.6 5.9 9.4 9.9 11.3 12.1 9.5 10.8 11.7 13.9 10.2 14.6 11.4 14.7 12.5 13.6 14.8 17.3 11.2 13.8 18.2 15.2 26.4 17.7 18.6 1.9 2.1 0.8 0.3 0.1 0.2 0.4 0.4 0.4 0.4

DSO

114.1 104.3 76.5 - 104.6 117.1 94.8 - 803.0 - 183.1 - 26.5 - - - - - - - - - - - 120.0 177.1 38.6 71.7 59.9 64.6 73.1 84.9 121.0 87.0 68.6 94.2 106.8 13.5 9.7 21.7 53.7 20.7 15.2 - 9.8 29.5 - - - - - - - - - - - - - -

DIO

- - - - - 47815.0 16082.8 - - - - - - - - - - - - - - - - - 1231.9 130.3 151.5 702.2 951.3 949.0 860.5 - 251.2 145.5 153.8 - 166.4 56.5 68.8 - - - - - - - - - - - - - - - - - - - - -

DPO

- - - - 30774.1 70171.2 39830.6 - - - - - - - - - - - - - - - - - 3418.4 107.2 179.6 581.7 500.1 385.5 392.4 - 211.9 157.4 262.9 - 317.6 72.9 103.1 - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

114.1 104.3 76.5 - 104.6 47932.1 16177.6 - 803.0 - 183.1 - 26.5 - - - - - - - - - - - 1351.9 307.5 190.1 773.9 1011.1 1013.6 933.6 84.9 372.2 232.6 222.3 94.2 273.1 70.0 78.5 21.7 53.7 20.7 15.2 - 9.8 29.5 - - - - - - - - - - - - - -

Cash Conversion Cycle

114.1 104.3 76.5 - -30669.5 -22239.2 -23653.0 - 803.0 - 183.1 - 26.5 - - - - - - - - - - - -2066.5 200.3 10.5 192.2 511.1 628.1 541.2 84.9 160.3 75.2 -40.6 94.2 -44.5 -2.9 -24.6 21.7 53.7 20.7 15.2 - 9.8 29.5 - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Organovo Holdings, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Neogen Corporation Neogen Corporation
NEOG
$ 9.4 2.29 % $ 2.04 B usaUSA
Natera Natera
NTRA
$ 253.82 0.63 % $ 34.7 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Celcuity Celcuity
CELC
$ 83.26 0.97 % $ 3.89 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.1 2.19 % $ 24.7 B niderlandNiderland
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Personalis Personalis
PSNL
$ 11.73 -1.26 % $ 1.05 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 16.5 -1.02 % $ 695 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Co-Diagnostics Co-Diagnostics
CODX
$ 1.51 7.09 % $ 2.01 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Neuronetics Neuronetics
STIM
$ 1.82 -2.67 % $ 120 M usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 35.41 -0.95 % $ 1.89 B usaUSA
NeoGenomics NeoGenomics
NEO
$ 15.27 13.96 % $ 1.96 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Waters Corporation Waters Corporation
WAT
$ 379.48 -1.15 % $ 22.6 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 584.93 2.44 % $ 16.9 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.22 -0.31 % $ 26.1 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Exagen Exagen
XGN
$ 4.35 -2.25 % $ 93.8 M usaUSA
Biomerica Biomerica
BMRA
$ 1.59 -0.62 % $ 3.65 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.1 -5.27 % $ 28.3 M israelIsrael
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 -1.14 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
DexCom DexCom
DXCM
$ 75.14 0.39 % $ 29.3 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.37 -17.27 % $ 1.03 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 178.18 -1.14 % $ 14 B irlandaIrlanda
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA